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Systemic lupus erythematosus (SLE) is a heterogeneous, 
multi-system autoimmune disease that presents with a 
wide  range  of  clinical  and  laboratory  abnormalities. 
Challenges in the clinical management of SLE include the 
identification of new and relevant therapeutic targets and 
of  specific  biomarkers  that  can  be  used  to  optimize 
diagnosis,  assessment  of  disease  activity  (severity  of 
disease) and prediction of flares (periodic worsening of 
symptoms).  DNA  microarray  technology  allows  a 
hypothesis-free method to comprehensively identify the 
genes and biological pathways that are associated with 
clinically  defined  conditions.  For  SLE,  the  blood  is  an 
easily  accessible  compartment  for  monitoring  immune 
pathophysiology  by  microarray  analysis.  Accordingly, 
several publications have reported microarray studies of 
peripheral  blood  cells  to  identify  gene  expression 
signatures  in  SLE.  These  studies  mainly  confirm  and 
extend the central role of the type I interferons in SLE [1]. 
In  the  May  issue  of  BMC  Medicine,  Arasappan  and 
colleagues [1] describe a new meta-analysis method that 
allows analysis across different DNA-microarray datasets 
to identify genes and processes relevant to SLE.
Meta-analysis across DNA-microarray datasets
Because of the complexity of microarray technology and 
frequently sub-optimally powered studies, verification of 
results is an essential step in microarray analysis. There  fore, 
combining analyses from different studies is important 
for increasing power, reliability and validation. However, 
several important challenges need to be considered when 
integrating microarray datasets for meta-analysis. First, 
sample  collection,  annotation,  pro  cess  ing  and  prepara-
tion need to be performed according to quality controlled 
and  compatible,  preferably  standardized,  procedures. 
There  is  considerable  inter-individual  variability  in  the 
transcriptomes of SLE patients, which is inherent to the 
heterogeneity of the disease and affects analyses. Second, 
good laboratory techniques for data acquisition need to 
be used. Third, appropriate and properly used data analysis 
practices  are  required.  In  order  to  establish  quality 
criteria  and  allow  comparisons  across  independent 
datasets, standards for microarray experiments and data 
analysis  were  created  [2].  Recent  reports  from  the 
Microarray  Quality  Control  (MAQC)  consortium 
confirm that microarray technology is robust and should 
be  able  to  reliably  reveal  differentially  expressed  genes 
across samples using different datasets [3].
Several approaches have been used for meta-analysis of 
microarray  data  to  enable  comparative  analyses  across 
multiple  datasets,  to  minimize  noise  and  to  generate 
multivariate  metrics  for  clinical  use.  Initial  studies 
compared statistical measures of differentially expressed 
genes  for  each  dataset  to  classify  samples.  Others 
revealed  that  the  concordance  between  datasets 
improved  markedly  when  the  quantity  of  differential 
expression was used for gene selection, rather than the 
statistical  significance  [4].  Alternatively,  the  inter-gene 
correlations  between  datasets  and  a  ‘meta-review’ 
method for ranking genes using the genuine published 
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© 2011 BioMed Central Ltdevidence  for  each  study  have  been  applied.  All  these 
approaches are gene-based, that is, they aimed to identify 
commonly expressed genes between studies.
Application of DNA-microarray meta-analysis 
methods to SLE
Arasappan and colleagues [1] present a new strategy for 
microarray meta-analysis that is based on the identifica-
tion  of  pathways  that  are  coordinately  expressed  in 
multiple disease datasets. They used as input microarray 
datasets  of  peripheral  blood  mononuclear  cell  samples 
obtained from SLE patients, and healthy controls derived 
from four different studies, of which two involved only 
children and the other two only adults. Transcriptional 
profiles  were  generated  and  low  stringency  and  fold 
change  cut-offs  were  applied  to  select  differentially 
expressed  genes.  For  each  dataset,  Ingenuity  Pathway 
Analysis  was  used  to  identify  biological  pathways  that 
were differentially expressed between SLE patients and 
controls. Validation with the leave-one-out permutations 
method  revealed  three  main  biological  pathways  that 
were consistently enriched in SLE patients. Subsequently, 
a  meta-signature  consisting  of  37  genes  involved  in 
diverse  processes  was  generated.  Each  gene  that  was 
selected met the original criteria, was involved in at least 
one relevant pathway and had a fold change of over 2 in 
at least one of the datasets. This signature differentiated 
well between children with SLE and healthy controls in a 
fifth independent dataset.
Comparison  of  SLE  with  healthy  controls  could 
generate insights into the underlying immune dysfunction 
and  thus  help  identify  therapeutic  targets  for  SLE. 
Signatures that were found to be consistently enriched 
between the different datasets included interferon signal-
ing,  corroborating  and  extending  earlier  findings,  and 
interleukin-10 signaling, which may reflect a dysregulated 
inflammatory process linked to humoral immune activa-
tion and Janus kinase (JAK)/signal transducer and activator 
of transcription (STAT) signaling. Finally, a glucocorti-
coid  receptor  signaling  signature  was  also  implicated, 
although corticosteroid therapy, frequently used for SLE, 
may be a confounding factor. Specific signatures such as 
the  (low  density)  neutrophil,  immuno  globulin  and 
lymphopenic signatures that were previously reported to be 
part of one of the datasets [5] were not listed.
Interestingly, no differences between the children and 
adults with SLE were observed [1]. This finding supports 
observations  from  studies  directly  and  indirectly 
comparing  cohorts  of  children  and  adults  with  SLE, 
which revealed that no known unique physiological or 
genetic  pathways  were  identified  that  can  explain  the 
variability in the disease phenotypes [6].
Overall, the pathway-based approach of Arasappan and 
colleagues [1] seems to offer a simple and valuable way to 
increase  the  power  of  microarray  data  meta-analysis. 
Using  different  pathway-level  stringencies  and 
approaches,  such  as  Gene  Set  Enrichment  Analysis, 
PANTHER  and  Metacore  for  confirmation  of  pathway 
signatures,  may  increase  the  robustness  of  the  results. 
The  value  of  the  different  meta-analysis  methods  will 
become  apparent  in  comparative  studies.  Such 
benchmarking, together with incorporation of properly 
annotated  demographic  and  clinical  data,  would  allow 
optimization of meta-analysis approaches.
Next steps
The future challenge is to use meta-analysis strategies to 
identify gene signatures and biomarkers that can improve 
measures for diagnosis and disease activity in SLE.
In an attempt to use a blood leukocyte gene expression 
profile to improve the diagnosis of SLE, Chaussabel and 
colleagues  [7]  went  one  step  further  and  compared  a 
dataset  from  SLE  with  datasets  from  several  other 
diseases,  including  those  that  show  an  interferon 
signature. To compare datasets across multiple diseases, 
they used a custom meta-analysis strategy for diagnostic 
biomarker  selection  using  statistical  significance  (P  < 
0.01),  rather  than  the  preferable  gene  expression  size 
effects  between  each  group  of  patients  versus  healthy 
controls.  Subsequent  selection  of  genes  that  reached 
significance  for  the  comparison  between  SLE  patients 
and  healthy  controls,  and  not  compared  to  healthy 
subjects in the other diseases, led to the identification of 
an SLE-specific ‘diagnostic signature’ that differentiates 
SLE patients from patients with diseases that also show 
an interferon signature [7].
The SLE disease activity index (SLEDAI) consists of a 
series of measures that is sometimes difficult to obtain, so 
development of a simple and objective index based on a 
blood leukocyte gene expression profile would be useful. 
Arasappan and colleagues [1] provide evidence that their 
37-gene  meta-signature  discriminates  between  patients 
with a low (<3) and high (>3) SLEDAI score, confirming 
results from other independent studies. One such study 
was  performed  by  Chaussabel  and  colleagues  [8],  who 
used  a  ‘modular  analysis  framework’  based  on  the 
identification of coordinately expressed genes in disease 
datasets  that  form  transcriptional  modules.  Their 
approach predicted severity of disease more accurately 
than the SLEDAI in some cases, demonstrating that the 
blood leukocyte gene expression profile might be useful 
for  discovering  diagnostic  and  prognostic  biomarkers 
and monitoring disease progression.
Towards a systems biology approach
Unique to transcriptome analyses is the identification of 
gene signatures that represent biological networks, such 
as  the  interferon  system,  that  are  relevant  in  disease 
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systems biology approach. Successive research activities 
on  these  networks,  together  with  approaches  using 
complementary  platforms  such  as  (epi)genetics,  multi-
plex  fluorescence-activated  cell  sorting  and  advanced 
metabolomics/proteomics, will provide a complete insight 
into the mechanism and other network components of 
processes and pathways relevant to disease. For example, 
interferon-based genetic studies led to the identification 
of polymorphisms that are strongly associated with SLE 
in genes encoding interferon regulatory factor 5 (IRF5), 
STAT4,  interleukin-1  receptor-associated  kinase  1 
(IRAK1), autophagy protein 5 (ATG5) and three prime 
repair  exonuclease  1  (TREX1),  genes  that  are  all 
connected  with  deregulated  interferon  activity  [9]. 
Proteomics on downstream components revealed that a 
composite chemokine score for the interferon-regulated 
chemokines CXCL10 (IP-10), CCL2 (MCP-1) and CCL19 
(MIP-3B) in patients with a SLEDAI of 4 or less were 
predictive of a lupus flare over the ensuing year [10].
Thus,  besides  identifying  clinically  relevant 
transcriptome  markers,  DNA-microarray  technology 
provides a basis for an evidence-based systems biology 
approach  to  delineate  pathogenic  processes  and  reveal 
other  relevant  markers.  Meta-analysis  methods  will  be 
instrumental  in  helping  to  select  those  exploratory 
markers for further biomarker validation, which will pave 
the way for clinical development and benefit patients.
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